A Single Treatment with a Specific Chymase Inhibitor, TY-51184, Prevents Vascular Proliferation in Canine Grafted Veins

Journal of Pharmacological Sciences

Volumn 94, Issue 4, 2004, Pages 443-448

  Takai, Shinji ^a   Jin, Denan ^a   Sakaguchi, Masato ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chymase; Graft; Inhibitor; Vascular proliferation

Indexed keywords

2 [4 (5 FLUORO 3 METHYLBENZO[B]THIOPHEN 2 YL)SULFONAMIDO 3 METHANESULFONYLPHENYL]OXAZOLE 4 CARBOXYLIC ACID; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; SODIUM CHLORIDE; TY 51184; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DOG; DRUG SPECIFICITY; ENZYME ACTIVITY; JUGULAR VEIN; NONHUMAN; VEIN GRAFT;

EID: 2342568458     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.94.443     Document Type: Article

References (29)

1. Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol. 1994;24 Suppl 2:S6-S13.
2. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
3. Kim S, Iwao H. Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling. J Pharmacol Sci. 2003;91:177-181.
4. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta. 1997;265:13-20.
5. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412:86-90.
6. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta. 2000;1480:245-257.
7. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 1996;58:591-597.
8. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta. 2001;305:191-195.
9. Takai S, Miyazaki M. Effect of chymase inhibitor on vascular proliferation. Jpn J Pharmacol. 2002;90:223-227.
10. Powell JS, Clozel JP, Muler RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1991;245:186-188.
11. Roux SP, Clozel JP, Kuhn H. Cilazapril inhibits wall thickening of vein bypass graft in the rat. Hypertension. 1991;18 Suppl 4:II43-II46.
12. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci. 1991;49:PL223-PL228.
13. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation. 1992;86:100-110.
14. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2 /C lesions: the VAL-PREST trial. J Invasive Cardiol. 2001;13: 93-97.
15. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens. 1999;13 Suppl 1:S21-S25.
16. Yuda A, Takai S, Jin D, et al. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci. 2000;68:41-48.
17. Takai S, Yuda A, Jin D, et al. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 2000; 467:141-144.
18. Caughey GH. Serine proteinases of mast cell and leukocyte granules. A league of their own. Am J Respir Crit Care Med. 1994;150:S138-S142.
19. Oleksyszyn J, Powers JC. Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases. Methods Enzymol. 1994;244:423-441.
20. Koide Y, Tatsui A, Hasegawa T, et al. Identification of a stable chymase inhibitor using a pharmacophore-based database search. Bioorg Med Chem Lett. 2003;13:25-29.
21. Okamoto Y, Takai S, Miyazaki M. Significance of chymase inhibition for prevention of adhesion formation. Eur J Pharmacol. 2004;484:357-359.
22. Nishimoto M, Takai S, Kim S, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 2001;104:1274-1279.
23. Sauvage LR, Wu HD, Kowalsky TE, et al. Healing basis and surgical techniques for complete revascularization of the left ventricle using only the internal mammary arteries. Ann Thorac Surg. 1986;42:449-465.
24. Green GE, Stertzer SH, Reppert EH. Coronary arterial bypass grafts. Ann Thorac Surg. 1968;5:443-450.
25. Urschel HC, Miller ER, Razzuk MA, Alvares JF, McNamara JJ, Paulson DL. Aorta-to-coronary-artery vein bypass graft for coronary artery occlusive disease. Ann Thorac Surg. 1969;8: 114-125.
26. Fuchs JC, Mitchener JS, Hagen PO. Postoperative changes in autologous vein grafts. Ann Surg. 1978;188:1-15.
27. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg. 1985;89:248-258.
28. Borland JA, Chester AH, Crabbe S, Parkerson JB, Catravas JD, Yacoub MH. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts. J Thorac Cardiovasc Surg. 1998;116:206-212.
29. Nishimoto M, Takai S, Sawada Y, et al. Chymase-dependent angiotensin 11 formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg. 2001;121: 729-734.